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A granuloma is defined as an inflammatory mononuclear cell infiltrate that, while capable of
limiting growth of Mycobacterium tuberculosis, also provides a survival niche from which
the bacteria may disseminate. The tuberculosis lesion is highly dynamic and shaped by
both, immune response elements and the pathogen. In the granuloma, M. tuberculosis
switches to a non-replicating but energy-generating life style whose detailed molecular
characterization can identify novel targets for chemotherapy. To secure transmission to a
new host, M. tuberculosis has evolved to drive T cell immunity to the point that necro-
tizing granulomas leak into bronchial cavities to facilitate expectoration of bacilli. From an
evolutionary perspective it is therefore questionable whether vaccination and immunity
enhancing strategies that merely mimic the natural immune response directed against M.
tuberculosis infection can overcome pulmonary tuberculosis in the adult population. Juxta-
position of molecular pathology and immunology with microbial physiology and the use of
novel imaging approaches afford an integrative view of the granuloma’s contribution to the
life cycle of M. tuberculosis. This review revisits the different input of innate and adaptive
immunity in granuloma biogenesis, with a focus on the co-evolutionary forces that redirect
immune responses also to the benefit of the pathogen, i.e., its survival, propagation, and
transmission.
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INTRODUCTION
The pathogenesis of tuberculosis used to be the investigative
domain of two relatively separate, albeit complementary disci-
plines. On the one hand, molecular microbiologists decoded the
survival strategies of Mycobacterium tuberculosis (M. tuberculosis),
i.e., physiological and metabolic adaptation to the host environ-
ment, dynamics of replication, and synthesis and structures of
the cell wall in order to define microbial factors important for
virulence and persistence. On the other hand, infection immunol-
ogists analyzed innate and adaptive immune responses required
to contain M. tuberculosis growth and dissemination, often wel-
coming the pathologist’s view on granuloma initiation, main-
tenance, and disintegration. In recent years, a more integrated
view of tuberculosis pathogenesis has prevailed: the granuloma
is not only recognized as a tissue reaction to limit bacillary
growth and sequester infection but also as part of the success-
ful life cycle of M. tuberculosis, thus representing the dynamic
combat zone between both, the pathogen and host defense ele-
ments. This co-evolutionary perspective emphasizes the mutual
shaping of the tissue microenvironment, which, at the same
time, allows propagation and transmission of M. tuberculosis,
yet restricts tissue damage to safeguard survival of the host.
This review will highlight recent findings that have shifted the
long-held paradigm that in TB the granuloma is primarily or
uniquely relevant for protection of the host. This integrative model
of the granuloma’s function in TB pathogenesis also challenges
the concept that granulomas exclusively serve the interest of the
pathogen.
INCIPIENT GRANULOMAS: FERTILE SOIL FOR
MYCOBACTERIAL REPLICATION
After aerosol inhalation, the first host cell M. tuberculosis encoun-
ters is the alveolar macrophage, which phagocytoses but fails to kill
the mycobacterial invaders, but does produce chemoattractants.
Chemokines produced by alveolar macrophage and pneumocytes
attract the first round of inflammatory cells, i.e., neutrophils,
monocyte derived macrophages, NK cells, and γδ-T cells, which
further promote inflammation and tissue remodeling (Feng et al.,
2006; Lockhart et al., 2006; Eum et al., 2010). In mouse models of
aerosol infection with mycobacteria, granuloma formation pro-
ceeds in the complete absence of specific immunity (North and
Izzo, 1993; Hänsch et al., 1996; Smith et al., 1997). While TNF-α
and IFN-γ accelerate inflammatory cell infiltration, they are not
essential for granuloma initiation (Flynn et al., 1995; Smith et al.,
1997). Non-activated macrophages, however, serve as feeder cells
within the nascent granuloma (Davis and Ramakrishnan, 2009;
Ehlers, 2010). Indeed, in the transparent zebrafish embryo model
of M. marinum infection, a single virulence factor, which is present
also in M. tuberculosis, ESAT6, is sufficient to induce matrix met-
alloprotease 9 production in epithelial cells (Volkman et al., 2010).
This results in the recruitment of resting macrophages in which
M. marinum replicates, and which even function as vectors that
www.frontiersin.org January 2013 | Volume 3 | Article 411 | 1
Ehlers and Schaible TB granulomas: a host–pathogen collusion
spread infection to other body tissues (Davis and Ramakrishnan,
2009). In sum, early innate responses to M. tuberculosis infection
do little to restrict and much to promote M. tuberculosis replica-
tion. Consequently, a focal accumulation of mononuclear cells in
various states of differentiation, i.e., the initial stage of a granu-
loma, is not per se protective. Therefore it is no big surprise that
the lack of the innate Toll-like or NOD-like receptors in mice,
though involved in recognition of mycobacteria and subsequent
induction of inflammation, has no major impact on the course
of aerosol M. tuberculosis infection (Gandotra et al., 2007; Reiling
et al., 2007; Walter et al., 2010). Similarly, C-type lectins including
mannose receptor, CD38, DC-SIGN, or MINCLE, all recognizing
various mycobacterial cell wall glycolipids, do not contribute much
to protection, most probably due to a high degree of redundancy
between those receptors (Court et al., 2010; Behler et al., 2012;
Heitmann et al., 2012). It should however be mentioned that the
mycobacterial glycolipid ligand of Mincle, trehalose dimycolate,
alone is sufficient to induce inflammation and granuloma-like
structures upon injection into mice, which is diminished in Min-
cle KO mice (Geisel et al., 2005; Ishikawa et al., 2009; Schoenen
et al., 2010; Lee et al., 2012). Trehalose dimycolate, a mycobacterial
virulence factor on its own right, may therefore represent a driving
force in granuloma formation.
MATURE GRANULOMAS: DYNAMIC HETEROGENEITY
Following migration from the initial inflammatory focus to the
regional lymph nodes, dendritic cells prime T cells for differen-
tiation into predominantly TH1 and TH17 as well as cytotoxic
T effector cells (Cooper, 2009). Recirculating primed pathogen
specific T cells are critical for activating macrophages and curtail
mycobacterial growth within the nascent granulomatous lesion
(North and Jung, 2004). In the presence of activated T cells, the
granuloma becomes fully organized, with mycobacteria-harboring
macrophages at the center surrounded by a rim of lymphocytes.
The ensuing stale-mate between host and pathogen, however, is
much more dynamic than previously thought, and involves con-
tinuous loss of cells by cell death and replenishment by cellular
recruitment, as well as vascular and tissue remodeling (Figure 1).
Apart from inflammatory immune cells also mesenchymal stem
cells are recruited, which seem to promote infection (Raghuvanshi
et al., 2010). Pathologists have long been enamored with describing
tuberculosis lesions as “exsudative, suppurative, miliary, caseous,
circumscribed, fibro-calcified,”and so on. A relatively recent analy-
sis of lung lesions removed by surgery focused on two highly
disparate structures, cavitary lesions and tuberculomas (Ulrichs
and Kaufmann, 2006). Cavities were surrounded by few vessels
and a diffuse pattern of proliferating cells, while tuberculomas
exhibited a highly organized framework of follicle-like structures
and high vascularization.
By describing variety and heterogeneity, pathologists have often
tried to place different types of lesions in a seemingly logical
temporal sequence to one another, insinuating developmental
relationships (Dannenberg and Rook, 1994). Using sophisticated
in vivo imaging reporter technology with molecular probes detect-
ing host tissue metabolism as a measure for inflammatory activity,
scientists are currently re-discovering this enormous heterogeneity
of tuberculosis lesions, with the pioneers’ advantage of following
the same granuloma over time (Barry et al., 2009). Thus, “centro-
acinary, perifocal, tree-in-bud, metabolically active” have become
useful phenotypic labels identifying several distinct types of lesions
co-existing within a single individual. More surprisingly, these
lesions may independently regress, and even vanish over time,
while others flourish and exacerbate even under treatment (Barry
et al., 2009; Lin and Flynn, 2010). There does not appear to be a
clear linear relationship between these lesions, but rather a contin-
uous spectrum. Macrophages within infiltrates form a scaffold to
direct the movement of lymphocytes in search of antigenic stimu-
lation (Egen et al., 2008, 2011), but both, a delay in T cell arrival as
well as inhibition of T cell responses within the lesion account for a
heterogeneous antimicrobial response and persistence of tubercle
bacilli.
One theory contends that, even during latency, macrophages
from time to time egress from the lesion and spread the infec-
tion to other parts of the lung (Cardona and Ruiz-Manzano,
2004; Cardona, 2009). Although this defies the very definition
of a latent infection since migration of infective macrophages
through the airspaces would effectively make this latent infec-
tion a patent one, it may reflect the flaring-up of quiescent
lesions during apparent “latency.” A consensus is emerging that
not only active, but also latent disease shows a spectrum of
lesional activity (Lin et al., 2009). In this respect, in vivo imaging
may for the first time deliver functional classifications of diverse
“latency” stages, superseding the current rather static description
of lasting immune responsiveness to an infectious stimulus that
occurred in the past (Mack et al., 2009). It would be interest-
ing to apply the imaging approach to screen clinically healthy
individuals in high-transmission populations for incipient active
lesions. Therapeutic consequences are evident, in that the iden-
tification of functional biomarkers indicating latent infections
would permit specific preventive chemotherapy of those individ-
uals at greatest risk for reactivating tuberculosis (Russell et al.,
2010). Interferon-α and neutrophil driven transcriptome signa-
tures have recently been described as markers of susceptibility to
active human tuberculosis (Berry et al., 2010). Experimentally, the
absence of IFN-αβ signaling in mice improved outcome after infec-
tion with highly virulent but not with attenuated (Cooper et al.,
2000; Manca et al., 2001), strains of M. tuberculosis, and genetically
susceptible mouse strains survived longer when neutrophils were
depleted (Keller et al., 2006). Whether these signatures can serve
as prospective susceptibility markers for preventive treatment of
latent tuberculosis patients has to be proven in longitudinal stud-
ies in high-transmission populations (Berry et al., 2010). One
caveat is that some of these “biomarkers” may not be entirely
specific for tuberculosis, but rather indicative of other chronic
granulomatous conditions such as sarcoidosis (Maertzdorf et al.,
2012).
A number of animal model systems, ranging from mice, guinea
pigs, rabbits, minipigs, to marmoset, cynomolgous, and macaque
non-human primates, are in use to depict various aspects of gran-
uloma immunopathology. No single model system is perfect, but
they all reflect individual aspects of human tuberculosis and, if
taken with a grain of salt, contribute to stratifying the complexity
of pathology in humans, which cannot yet be examined directly in
molecular detail at the lesional site in humans. What has become
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FIGURE 1 | Dynamics of granuloma formation and pathology in
tuberculosis. M. tuberculosis (Mtb) elicits a local inflammatory infiltrate
which may give rise to (i) protective immunity, (ii) balanced inflammation
(i.e., control of Mtb growth with little tissue damage), or (iii) endobronchial
transmission following granuloma necrosis. The depicted types of organized
granulomas are idealized and represent stages of a pathophysiological
continuum. At the same time, they represent stages of the Mtb life cycle
with either retarded growth or metabolic adaptation within the
granulomatous lesion, or recrudescence and spreading to the next host
following granuloma disruption. Italics indicate typical cellular and humoral
mediators involved in granuloma differentiation which are addressed in more
detail in the text.
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most evident from analyzing the diversity of granulomas is that no
cross-sectional or even systemic marker can adequately represent
the succinctly local microenvironments of pulmonary granulo-
mas. Therefore, biomarker development is facing a formidable
challenge!
VERSATILE METABOLISMWITHIN GRANULOMAS:
NON-REPLICATING PERSISTENCE OFM. TUBERCULOSIS
Gluconeogenesis is necessary for M. tuberculosis throughout the
infection, i.e., not only in the phase of persistence, and phospho-
enolpyruvate kinase is the critical gate enzyme (Marrero et al.,
2010). Within the granuloma, it is assumed that M. tuberculosis
replicates only very little, but remains fully capable of generating
energy (see Figure 1). Genome-wide expression profiling of M.
tuberculosis RNA isolated from chronically infected mouse lungs
or sputum of tuberculosis patients revealed transcriptional sig-
natures reflective of environmental conditions such as low pH,
oxygen depletion, iron limitation, nitrosative stress, and nutrient
starvation (Timm et al., 2003; Voskuil et al., 2004; Talaat et al.,
2007; Garton et al., 2008). This explains the attenuated phenotype
of mutant M. tuberculosis defective in the leucin, lysine, purine, or
pantothenate biosynthetic pathways, or which are deficient in iron
acquisition or the stringent response (Boshoff and Barry, 2005).
The DosR regulon is a genetic program that critically governs
survival in the absence of respiration (Leistikow et al., 2010). The
conserved presence of long sequences of the DosR regulon in envi-
ronmental mycobacteria suggests that it did not evolve specifically
for survival within the mammalian host. Instead, the regulon may
have evolved to cope with conditions within the environment
such as very low oxygen tension. Thus, in a hypothetical ances-
tral M. tuberculosis strain, DosR gene products may have allowed
the bacteria to survive in a specific niche in a non-replicating state,
ensuring positive selection (Bartek et al., 2009).
Using a dual staining approach, three M. tuberculosis subpop-
ulations were found in hypoxic culture and in lung sections of
mice and guinea pigs. Bacteria were either exclusively acid-fast
positive, exclusively immunofluorescent positive or acid-fast and
immunofluorescent positive (Ryan et al., 2010). These results sug-
gest that M. tuberculosis exists as multiple populations with distinct
cell wall properties even within a seemingly single microenviron-
ment, advocating the development of analytical tools at the single
cell level. Indeed, intracellular mycobacteria have altered cell wall
lipid pattern as those grown in broth (Fischer et al., 2001). Evi-
dence from guinea pigs treated with antibiotics indicates that M.
tuberculosis may persist extracellularly within biofilm-like struc-
tures that consist of DNA and neutrophil debris, in a hypoxic
and iron-rich environment with incomplete dystrophic calcifica-
tion (Lenaerts et al., 2007). These biofilms appear similar to those
shown for biofilms of another lung pathogen, Pseudomonas aerug-
inosa (Parks et al., 2009). These niches where access of antibiotics
is likely compromised may serve as the primary sites of disease
reactivation, and mimicking these tissue conditions in axenic cul-
ture will be essential for successful in vitro compound screening
for next generation anti-mycobacterials.
Even when the drugs reach the bacteria, the actual mechanism
of killing M. tuberculosis remains unclear for most anti-
tuberculosis drugs. A case in point is isoniazid. It is generally
assumed that INH is only effective on actively replicating M.
tuberculosis. The fact that INH preventive chemotherapy can
reduce the level of tuberculosis manifestation in individuals diag-
nosed with latent infection has been a major argument for the
contention that quiescent tuberculosis lesions contain actively
dividing M. tuberculosis (Diel et al., 2008). It is clear that INH,
following its activation by the catalase peroxidase KatG, inhibits
mycolic acid synthesis. More specifically, an INH-NAD adduct
inhibits the fatty acid synthase II enoyl-ACP reductase InhA, lead-
ing to the accumulation of long-chain fatty acids (Vilcheze and
Jacobs, 2007). How exactly this precipitates M. tuberculosis death,
however, is the subject of ongoing investigations at the single cell
level within calibrated fermentation chambers, using fluorescent
reporter probes (Golchin et al., 2012).
Detailing the mechanisms and kinetics of how drugs kill M.
tuberculosis in vitro will be a crucial initial step for improving
anti-tuberculosis drug efficacy. An even more challenging task will
be to define and refine how drugs penetrate and work effectively
within tuberculosis lesions. This requires full knowledge of the tis-
sue microenvironment influenced by both, mycobacteria as well
as host responses, and includes micronutrient availability for both
“partners,” defense cells and microbe. Innovative imaging tech-
niques paired with fluorescent or luminescent reporter strains of
M. tuberculosis are important tools for monitoring pathogenesis
in situ and drug efficacy testing (Andreu et al., 2010; Carroll et al.,
2010; Kong et al., 2010; Zelmer et al., 2012). Of even greater interest
will be M. tuberculosis sensor strains, which can report physico-
chemical conditions in situ such as low iron concentration or drug
exposure.
How does M. tuberculosis exit the state of seeming dormancy
and resume growth? It may take one cue from the production of
resuscitation promoting factors (Rpf), RpfB being the most rele-
vant isoform out of five encoded in the M. tuberculosis genome
based on persistence assays with targeted deletion mutants (Kana
et al., 2008; see Figure 1). The structure of RpfB contains pecu-
liar features that are also shared by G5 domains involved in
biofilm formation (Ruggiero et al., 2009), providing a further
link to evolutionarily conserved pathways of adaptation to adverse
environmental conditions by changing growth patterns.
Foamy macrophages are key constituents of tuberculosis
lesions, representing macrophages packed with lipid bodies fol-
lowing activation via Toll-like receptors and proinflammatory
signals (D’Avila et al., 2006). These lipid bodies are the conse-
quence of an imbalance between the influx and efflux of low-
density lipoprotein particles from the serum. The phenotype can
be induced in vitro, in peripheral blood cells incubated with dis-
tinct mycobacteria-derived oxygenated ketomycolic and hydroxyl-
mycolic acids (Peyron et al., 2008). Lipid bodies may provide ideal
nutrition for a bacterium that is changing its metabolism to digest
fatty acids, as evidenced by upregulation of the gating enzyme
of the glyoxylate shunt, isocitrate lyase, and of the methylcitrate
pathway, methylcitrate dehydratase, in the intracellular life stage
(McKinney et al., 2000; Gould et al., 2006; Mattow et al., 2006;
Munoz-Elias et al., 2006).
Mycobacterium tuberculosis has also been shown to metabo-
lize cholesterol (Pandey and Sassetti, 2008), and several genes
such as Mce4, HsaC, and Icl1, which were previously linked
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to propionate metabolism, may be functionally linked through
cholesterol degradation. Cholesterol metabolism requires alter-
ing of transcription and metabolic profiles of M. tuberculosis to
access propionyl-CoA and pyruvate pools through the methyl-
citrate cycle. Consequently, gene deletion mutants therein are
handicapped for intracellular growth (Griffin et al., 2012). Analy-
sis of lipids from the caseum of human tuberculosis granulo-
mas revealed that the main lipid species are cholesterol, cho-
lesteryl ester, triacylglycerides, and lactosylceramide, implicating
low-density lipoprotein-derived lipids as the most likely source
(Kim et al., 2010). Granuloma necrosis, at least in mouse M.
tuberculosis or M. avium infection, is often associated with high
bacterial burden, and virulent mycobacteria can inhibit mem-
brane repair, which causes necrosis in infected macrophages
(Divangahi et al., 2009). A conceivable scenario, therefore, is
that the death of foamy macrophages results in the accumula-
tion of lipid debris making up the caseum at the center of the
granuloma (Russell et al., 2009; Behar et al., 2010). Other cells
may also contribute to cellular debris as neutrophils represent
a major cell population in TB lesions, which has an exquisitely
high death toll due to their short half-life and M. tuberculo-
sis driven necrosis (Eum et al., 2010; Corleis et al., 2012; see
Figure 1).
The initial necrotic nidus may be induced in the absence of
any adaptive immune response, as guinea pigs exhibit focal necro-
sis within granulomas as early as 10 days after infection (Turner
et al., 2003). Overwhelming experimental and clinical evidence,
however, suggests that promotion of full-fledged central caseation
in mycobacterial granulomas requires a hypersensitivity reaction,
precipitated by CD4+ T cells faced with a high antigenic load
(Dannenberg, 1991; Ehlers et al., 2001; Sanghi et al., 2011).
PREPARING FOR THE EXIT: GRANULOMA NECROSIS AS A
TRANSMISSION STRATEGY
There is much debate about whether tissue necrosis begins
with central necrotization of preformed granulomas, or whether
caseation and cavitation develop from so-called lipid pneumonia
accompanying regrowth of M. tuberculosis persisting outside of
granulomas (e.g., in epithelial cells, adipocytes, etc.; Hernandez-
Pando et al., 2000; Neyrolles et al., 2006). Evidence from the former
comes from studies in rabbits, guinea pigs, and designer mouse
models, while evidence for the latter is derived from histopatho-
logical studies in men and mice. For example, mice bearing
the sst-susceptible allele develop centrally necrotizing pulmonary
granulomas in which M. tuberculosis growth is rampant. The
host resistance gene, Ipr1, encoded within the sst1 locus, regu-
lates the infected macrophages’ mechanism of death (Kramnik,
2008). In dermally infected NOS2-deficient mice treated with a
neutralizing anti-IFN-γ antibody, established granulomas cen-
trally necrotize, showing signs of hypoxia and abundant cathepsin
G activity (Reece et al., 2010). In guinea pigs, necrosis within
granulomatous lesions can occur even before a robust T cell
response has developed (Turner et al., 2003). In rabbits, cavita-
tion has generally been attributed to a strong DTH response to
M. bovis infection precipitating caseation, cavitation, and lique-
faction of caseum within circumscript granulomas (Dannenberg
and Sugimoto, 1976; Dannenberg and Collins, 2001).
By examining a histological archive of tuberculosis lesions in
humans and revisiting the Cornell model of reactivation tuber-
culosis in mice, Hunter et al. (2007) came to the conclusion
that reactivation of M. tuberculosis infection begins as a lipid
pneumonia with bronchial obstruction and does not start from
disintegrating granulomas. A very potent component of M. tuber-
culosis to which this necrosis-inducing activity is attributed is cord
factor, or trehalose dimycolate which can induce inflammatory
infiltrates including foam cell formation but is also a virulence
factor promoting intracellular survival (Hunter et al., 2006; Kim
et al., 2010). Taken together, caseation appears to correlate with
pathogen-mediated dysregulation of host lipid metabolism.
As neutrophils represent the predominant cell population in
broncho-alveolar lavages of active tuberculosis patients they may
be more relevant in transmission of M. tuberculosis than in con-
trolling infection (Eum et al., 2010). Considerable controversy
exists over whether neutrophils are able to kill mycobacteria and a
recent review on the issue concluded that these otherwise potent
anti-bacterial effector cells fail to eliminate M. tuberculosis (Korbel
et al., 2008). Indeed, virulent M. tuberculosis quickly cause necrotic
cell death of human neutrophils upon infection in vitro by induc-
ing reactive oxygen intermediates (ROI) allowing the mycobacteria
to escape neutrophil-mediated killing. In contrast, an attenu-
ated M. tuberculosis mutant lacking the virulence associated RD1
region fails to induce necrosis and falls victim to neutrophils’
armamentarium, i.e., ROI (Corleis et al., 2012). More impor-
tantly, invading neutrophils with their payload of cytotoxic mol-
ecules may cause substantial tissue destruction and remodeling.
It can be envisaged that misguided but anti-microbially ineffec-
tive neutrophils invade existing (latent?) tuberculosis lesions and
prompt the immunopathological cascade toward active lesions,
providing further host cell lipid substrate for M. tuberculosis
growth and biofilm formation to secure subsequent transmission.
Here, super-infection with a novel M. tuberculosis strain or even
another unrelated co-infecting lung pathogen may represent an
as yet under-appreciated cause of reactivation (see Figure 1). In
addition, systemic co-infections of M. tuberculosis and unrelated
pathogens beyond HIV may also modulate lung immunity in the
latently infected. This was recently demonstrated in the murine
model of malaria-associated acute respiratory distress syndrome,
in which the mycobacterial burden was exacerbated in malaria – M.
tuberculosis co-infected mice (Mueller et al., 2012).
Sequencing the genomes of 21 M. tuberculosis strains repre-
sentative of the global diversity identified very little sequence
variation in 491 experimentally confirmed human T cell epi-
topes, indicating purifying selection (Comas et al., 2010). This
finding led to the hypothesis that M. tuberculosis benefits from
recognition by human T cells. In view of its confinement to the
granuloma, M. tuberculosis may have devised an exit strategy that
exploits T cell activation. TH1 responses (IFN-γ, IRF-1) were
shown to drive granuloma necrosis in a model of mycobacteria-
induced pulmonary immunopathology (Ehlers et al., 2001; Aly
et al., 2009), and TH2 responses have also been associated with
increased cavity formation and tissue destruction in humans and
mice (Rook, 2007); Hölscher, C., personal communication). Cav-
ity formation in rabbits, monkeys, and man are clearly results
of a long-lasting T cell-driven immune activation, low numbers
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of CD4+ cells virtually precluding granuloma necrosis (Chais-
son et al., 1987; Capuano et al., 2003). Moreover, AIDS patients
with tuberculosis have a different pathology and often, their spu-
tum is negative for acid-fast bacteria, further suggesting that
transmission-facilitating granulomas are immune driven (Aaron
et al., 2004, see Figure 1).
An integrated view of current findings would hold that individ-
ual components of M. tuberculosis, such as trehalose dimycolate,
allow for foam cell formation and macrophage necrosis, but full-
blown central necrosis of an established granuloma requires T cell
participation, either in the form of a hyperactive IFN-γ produc-
tion or a superimposed IL-4/IL-13 response. The latter induces
alternative macrophage activation (Gordon and Martinez, 2010),
and arginase 1 is a potential biomarker for reactivation tubercu-
losis and granulomas prone to necrotizing. Neutrophils, which
are also potent producers of arginase 1, may even amplify this
immunopathogenic cascade.
Are the “fat and lazy” persister bacilli present in the sputum
of cavitary patients specifically adapted for transmission (Garton
et al., 2008)? Very little is known about the physical parameters in
individual M. tuberculosis bacteria relevant for aerosolization, sur-
vival in the environment, or infectivity (i.e., inoculum“take” in the
alveolar macrophage; Fennelly et al., 2004). Also, there is a growing
debate as to whether low dose aerosol infection adequately reflects
the situation in endemic countries where exposure to putatively
larger numbers of coughed-up M. tuberculosis may be the crucial
factor overriding naturally existing or vaccine-induced immunity
(Rook et al., 2009).
THE BOTTOM LINE: DOESM. TUBERCULOSIS UNIVERSALLY
PROFIT FROM GRANULOMA FORMATION?
Given the recent focus on the stunning discovery that M. tuber-
culosis may direct granuloma induction and maturation as part
of its life cycle, the fact that, in the absence of granuloma for-
mation there is no protection, at least in the human host, has
been unduly neglected. Granulomas afford a unique juxtaposi-
tion of activating T cells and mycobacteria-laden macrophages,
and the temporal coincidence of T cell differentiation, granuloma
consolidation, and reduction of M. tuberculosis growth in all ani-
mal models that mimic human disease suggests causality (North
and Jung, 2004). It is important to emphasize that T cell memory
affords 10-fold lower bacterial loads in infected organs of vac-
cinated animals, and that the majority of bacteria reside within
granulomas and not randomly distributed throughout the body.
Therefore, while a mycobacteria-focused view on granulomas was
long overdue (Russell, 2007; Ramakrishnan, 2012), this should
by no means neutralize the evidence in favor of the protective
infection-sequestrating granuloma:
– T cells transfer protective immunity and granuloma formation
(Orme and Collins, 1983).
– HIV-infected individuals exhibit poor granulomatous inflam-
mation and poor control of mycobacterial growth (Lawn et al.,
2002).
– Macrophage accumulations (or innate granulomas) do not effi-
ciently kill mycobacteria unless activated by T cells (North and
Izzo, 1993; Smith et al., 1997).
– Interferon-gamma provided by NK cells alone is insufficient to
provide full protection in the absence of T cells (Feng et al.,
2006).
It is certainly true that the host-centric view has prevailed
for too long, neglecting the important input of M. tuberculosis
in shaping the granuloma to its advantage, but it is unwise to
underestimate the power of T cell-mediated macrophage activa-
tion, which takes place at the site of granulomatous inflammation,
as it currently provides the only venue for preventive vaccination
strategies.
CONCLUSION: IS IT POSSIBLE TO BE BETTER THAN NATURE?
One of the implications of the integrative view on M. tuberculo-
sis’ life cycle embraced here is that, to stop M. tuberculosis from
multiplying and transmitting, simple imitation, or augmentation
of the natural host response to infection is likely to fail. Unless
T cells can be trained to recognize M. tuberculosis as soon as it
enters the alveolar macrophage, one of the best vaccination strate-
gies might be to bypass the regulatory networks M. tuberculosis
itself initiates to establish its niche for replication. If anything,
vaccines would have to mitigate TH1 and TH2 responses and
altogether blunt regulatory T cell responses to allow more protec-
tive immunity while avoiding damaging pathology (Rook et al.,
2005). This may be impossible to achieve purely by vaccina-
tion, leaving ample opportunity for adjunct immunomodulatory
measures. Indeed, inhibition of inflammation may prove to be
a superior adjunct strategy to improve the outcome of antibi-
otic therapy (Churchyard et al., 2009). For example, blockade of
PDE4 together with INH shortened the duration of treatment by
one month and reduced pathology in a rabbit model of tubercu-
losis (Subbian et al., 2011). During the Immune Reconstitution
Inflammatory Syndrome (IRIS), which occurs in M. tuberculo-
sis-infected AIDS patients receiving highly active antiretroviral
therapy, corticosteroid therapy is highly effective. However, it
does not reproducibly interfere with TH1 responses but reduces
granzyme B and perforin levels, indicating an involvement of
CD8+T or NK cells in inflammatory exacerbation (Meintjes et al.,
2009).
A potential problem with current immunization strategies
against tuberculosis might be that they prime an immune response
to epitopes that have been highly conserved in M. tuberculosis,
because these dominant T cell targets ensure escape from the
granuloma and thus transmission. Indeed, in an alternative strat-
egy that refocused the T cell response to specificities that are not
normally recognized during natural infection, a more efficient
protection against murine M. tuberculosis infection was induced
than afforded by immunization with the immunodominant epi-
tope (Aagaard et al., 2009). This increased efficacy was associated
with elevated numbers of multifunctional T cells, producing TNF,
IFN-γ, and IL-2 at high levels.
Further considerations for improving vaccines take into
account that M. tuberculosis responds to the host immune response
by regulating and diversifying its own gene expression; for exam-
ple, during latency, stage-specific antigens are expressed that rep-
resent its metabolic adaptation and can effectively be utilized to
discriminate, by immunodiagnosis of host T cell responses against
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these antigens, between acute and latent infection (Demissie et al.,
2006). Based on these findings, a novel subunit combination
vaccine was developed: H56, comprising three M. tuberculosis
antigens, which are expressed either early in infection (Ag85,
ESAT6) or during the latent phase (Rv2660c), not only boosts
BCG-primed immunity but also induces multifunctional T cell-
mediated immune protection on its own before and after exposure
to M. tuberculosis (Aagaard et al., 2011). Ag85 is expressed by
both, BCG and M. tuberculosis, and is therefore responsible for
the boost effect, whereas ESAT6 is exclusive for the latter one and
expressed mostly during early, active replication stages. Rv2660c
however, is expressed during the entire course of infection in mice
(even by starved and dormant M. tuberculosis) but is only a weak
IFN-γ inducer by itself. It becomes mildly immunogenic only
when fused to Ag85-ESAT6 thereby obviating immune-mediated
exacerbation of the disease in infected individuals. In sum, the
selection and combination of antigens and epitopes specific for
different stages of TB may help outwit M. tuberculosis and control
reactivation.
It would be unreasonable to call the TB granuloma an unsuc-
cessful host defence, as it successfully contains the infectious focus
in more than 90% of cases. The 10% of individuals that progress
toward TB disease suffer from a disbalanced inflammatory reac-
tion, be it due to too little innate or adaptive immunity or due
to unrestrained hypersensitivity reactions. There is no balance
without a trade-off: in the case of TB this is the Janus face of T
cell immunity (which can be detrimental when overzealous). Any
intervention thus must be regulatory in nature rather than proin-
flammatory, and the rational design of therapies and vaccines must
take this into account.
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